{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:49:50Z","timestamp":1787230190554,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":3968,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/labinvest.2011.187","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T11:55:16Z","timestamp":1323690916000},"page":"371-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors"],"prefix":"10.1016","volume":"92","author":[{"given":"Yuji","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyo","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yokose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Koizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/labinvest.2011.187_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2008.10.011","article-title":"A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size","volume":"65","author":"Sakuma","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1038\/labinvest.2011.187_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1083\/jcb.124.4.619","article-title":"Disruption of epithelial cell-matrix interactions induces apoptosis","volume":"124","author":"Frisch","year":"1994","journal-title":"J Cell Biol"},{"key":"10.1038\/labinvest.2011.187_bib3","doi-asserted-by":"crossref","first-page":"9052","DOI":"10.1038\/sj.onc.1208091","article-title":"Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis","volume":"23","author":"Wei","year":"2004","journal-title":"Oncogene"},{"key":"10.1038\/labinvest.2011.187_bib4","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.1128\/MCB.01246-07","article-title":"CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma","volume":"27","author":"Uekita","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1038\/labinvest.2011.187_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/path.2676","article-title":"Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src","volume":"220","author":"Sakuma","year":"2010","journal-title":"J Pathol"},{"key":"10.1038\/labinvest.2011.187_bib6","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.2011.187_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc2615","article-title":"Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics","volume":"9","author":"Cragg","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/labinvest.2011.187_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3892\/or.2010.1123","article-title":"ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis","volume":"25","author":"Sakuma","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1038\/labinvest.2011.187_bib9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","article-title":"Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics","volume":"4","author":"Cragg","year":"2007","journal-title":"PLoS Med"},{"key":"10.1038\/labinvest.2011.187_bib10","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1371\/journal.pmed.0040294","article-title":"Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas","volume":"4","author":"Gong","year":"2007","journal-title":"PLoS Med"},{"key":"10.1038\/labinvest.2011.187_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/labinvest.2011.187_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/labinvest.2011.187_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1038\/labinvest.2011.187_bib14","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/0008-5472.CAN-05-4620","article-title":"Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival","volume":"66","author":"Song","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.2011.187_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2353\/ajpath.2007.060706","article-title":"SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines","volume":"170","author":"Zhang","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1038\/labinvest.2011.187_bib16","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/onc.2009.31","article-title":"The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants","volume":"28","author":"Chung","year":"2009","journal-title":"Oncogene"},{"key":"10.1038\/labinvest.2011.187_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"10.1038\/labinvest.2011.187_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4","article-title":"Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology","volume":"90","author":"Soldatenkov","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1038\/labinvest.2011.187_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/usp.28.1.15.21","article-title":"Agarose cell block: innovated technique for the processing of urine cytology for electron microscopy examination","volume":"28","author":"Mansy","year":"2004","journal-title":"Ultrastruct Pathol"},{"key":"10.1038\/labinvest.2011.187_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2353\/jmoldx.2006.060030","article-title":"Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay","volume":"8","author":"Matsukuma","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1038\/labinvest.2011.187_bib21","doi-asserted-by":"crossref","first-page":"15535","DOI":"10.1073\/pnas.1009472107","article-title":"TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer","volume":"107","author":"Yao","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/labinvest.2011.187_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1038\/labinvest.2011.187_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1038\/labinvest.2011.187_bib24","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2009.25.4029","article-title":"Phase I\/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer","volume":"28","author":"Haura","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/labinvest.2011.187_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.onc.1210684","article-title":"EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy","volume":"27","author":"Fu","year":"2008","journal-title":"Oncogene"},{"key":"10.1038\/labinvest.2011.187_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/labinvest.2011.187_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2169\/internalmedicine.50.4652","article-title":"Malignant pleural effusion from lung adenocarcinoma treated by gefitinib","volume":"50","author":"Kubo","year":"2011","journal-title":"Intern Med"},{"key":"10.1038\/labinvest.2011.187_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"key":"10.1038\/labinvest.2011.187_bib29","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-10-2668","article-title":"MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents","volume":"71","author":"Fan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.2011.187_bib30","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1073\/pnas.1109632108","article-title":"Asymmetric cancer cell division regulated by AKT","volume":"108","author":"Dey-Guha","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/labinvest.2011.187_bib31","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1535-7163.MCT-06-0761","article-title":"Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells","volume":"6","author":"Edwards","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/labinvest.2011.187_bib32","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","article-title":"Histone deacetylase inhibitors specifically kill nonproliferating tumour cells","volume":"23","author":"Burgess","year":"2004","journal-title":"Oncogene"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/labinvest2011187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/labinvest2011187","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722026988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722026988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/labinvest2011187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:51:16Z","timestamp":1758397876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722026988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0023683722026988"],"URL":"https:\/\/doi.org\/10.1038\/labinvest.2011.187","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/labinvest.2011.187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1038\/labinvest.2012.16","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}